Passage BIO, Inc. (PASG) stock
PASGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.25+0.24 (+5.99%)
Close on Nov 13, 2026Market cap $13.68MP/E –Yield –
Passage BIO total assets
Total assets on the balance sheet at the end of each period.
Passage BIO's total assets was $20.79M at Sep 30, 2026. For fiscal 2025 it was $62.28M, down 39.2% from the year before. The highest annual figure on record is $355.08M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.28M | -39.2% |
| FY2024 | Dec 31, 2024 | $102.41M | -32.0% |
| FY2023 | Dec 31, 2023 | $150.55M | -38.2% |
| FY2022 | Dec 31, 2022 | $243.55M | -31.4% |
| FY2021 | Dec 31, 2021 | $355.08M | +8.3% |
| FY2020 | Dec 31, 2020 | $328.01M | +83.6% |
| FY2019 | Dec 31, 2019 | $178.61M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $20.79M | -72.0% |
| Q2 FY2026 | Jun 30, 2026 | $25.18M | -68.2% |
| Q1 FY2026 | Mar 31, 2026 | $36.46M | -57.6% |
| Q4 FY2025 | Dec 31, 2025 | $62.28M | -39.2% |
| Q3 FY2025 | Sep 30, 2025 | $74.16M | -33.6% |
| Q2 FY2025 | Jun 30, 2025 | $79.20M | -36.8% |
| Q1 FY2025 | Mar 31, 2025 | $86.01M | -38.8% |
| Q4 FY2024 | Dec 31, 2024 | $102.41M | -32.0% |
| Q3 FY2024 | Sep 30, 2024 | $111.75M | -34.0% |
| Q2 FY2024 | Jun 30, 2024 | $125.39M | -35.3% |
| Q1 FY2024 | Mar 31, 2024 | $140.53M | -34.1% |
| Q4 FY2023 | Dec 31, 2023 | $150.55M | -38.2% |
| Q3 FY2023 | Sep 30, 2023 | $169.26M | -37.3% |
| Q2 FY2023 | Jun 30, 2023 | $193.70M | -35.3% |
| Q1 FY2023 | Mar 31, 2023 | $213.24M | -36.0% |
| Q4 FY2022 | Dec 31, 2022 | $243.55M | -31.4% |
| Q3 FY2022 | Sep 30, 2022 | $270.05M | -30.9% |
| Q2 FY2022 | Jun 30, 2022 | $299.42M | -31.9% |
| Q1 FY2022 | Mar 31, 2022 | $333.22M | -28.4% |
| Q4 FY2021 | Dec 31, 2021 | $355.08M | +8.3% |
| Q3 FY2021 | Sep 30, 2021 | $390.94M | +9.0% |
| Q2 FY2021 | Jun 30, 2021 | $439.53M | +16.2% |
| Q1 FY2021 | Mar 31, 2021 | $465.17M | +18.5% |
| Q4 FY2020 | Dec 31, 2020 | $328.01M | +83.6% |
| Q3 FY2020 | Sep 30, 2020 | $358.69M | – |
| Q2 FY2020 | Jun 30, 2020 | $378.10M | – |
| Q1 FY2020 | Mar 31, 2020 | $392.43M | – |
| Q4 FY2019 | Dec 31, 2019 | $178.61M | – |
See a number that looks wrong?